Less than one in 10 people that would benefit from obesity jabs such as Wegovy can access them, caution the World Health Organization as it releases its first recommendations on the medications.
With more than one billion individuals worldwide now classified as obese, it is urging increased and just access to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our new guidance affirms that obesity is a chronic disease that can be managed with comprehensive and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key hurdles to universal availability to the treatments that can aid individuals in losing substantial weight, explains the organization.
Skinny Jab Supply Crisis
Even under the present most favorable outlook, the manufacturing of these medications might only reach approximately 100 million people – less than 10% of those who need them, per the health organization.
The recommendation calls on countries and companies to expand access, via measures including patent sharing.
Exclusive production rights on the active ingredient – the core ingredient of the drug Wegovy – is due to expire in multiple countries in 2026.
The Way Obesity Drugs Function
GLP-1 drugs mimick a biological compound to slow digestion, reduce hunger and boost feelings of fullness so individuals reduce food intake.
Patients usually start to lose weight in the initial weeks of commencing the regular doses.
Evidence points to patients may put most of the weight back on a year later of discontinuing the drug, because their usual appetite resume.
Being carrying excess weight raises your likelihood for developing medical conditions, like diabetes, heart disease, brain attack, and specific malignancies.
Excess weight affects people in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, per the health agency.
